Kornimate/medical-research-clean huggingface dataset:
family members affected by substance use disorder - a follow-up study

Conditions: Caregiver Burden

Summary: the present study registration relates to a quantitative sub-study of a larger mixed method study, including also a qualitative sub-study. together, these investigations will provide complementary insights. the quantitative study is a follow-up study of close relatives (\> 16 years) of patients in treatment for substance use disorder (sud) who participated in a group-based 4-day psychoeducational program.

the study is a follow-up study of close relatives (\> 16 years) of patients in treatment for suds who participated in a group-based 4-day psychoeducational program. the investigators will examine whether the family intervention in the specialized treatment services has benefits in terms of typical patient reported outcomes; physical complaints, psychological functioning, family functioning and qol. the data collection has been finalized in 2017.

Eligibility criteria:
inclusion criteria: * all participants in a family program exclusion criteria: * none
68ga-dotatate pet/ct in neuroendocrine tumor

Conditions: Neuroendocrine Tumors

Summary: somatostatin receptor(sstr) was expressed in neuroendocrine tumor cells and sstr-targeting molecular imaging(68ga-dotatate pet/ct) could be a promising technique to evaluate the primary tumor and metastatic lesions of neuroendocrine tumors with higher accuracy. this prospective study is going to investigate whether radiolabeled somatostatin analogs 68ga-dotatate pet/ct may be valuable for diagnosis, risk stratification, and prognostic evaluation of neuroendocrine tumors and compared it with 18f-fdg pet/ct.

neuroendocrine tumor(net)can be derived from endocrine glands, endocrine tissues and endocrine cells from any parts of body. due to its occult onset and heterogeneity, it is hard to be detected by conventional imaging like ct and it is often at late stage when diagnosed. new imaging modality such as 18f-fdg pet/ct have been well-accepted as a practical way to evaluate the aggressive of tumor. 18f-fdg pet/ct has been used to improve the efficacy in assessing the extent and severity of net, but the diagnostic accuracy of 18f-fdg pet/ct decreased in low proliferation tumor cells and inflammation. recent studies showed somatostatin receptor (sstr) was expressed in net cells and sstr-targeting molecular imaging-68ga-dotatate pet/ct could be a promising technique to evaluate the extent of net with higher accuracy. especially in some well differentiated tumor, 18f-fdg pet/ct can be negative, while 68ga-dotatate pet/ct can be positive. however, the results can be varied in these two imaging modalities and characterized this disease at multiple levels such as clinical presentation, biologic characteristics, treatment response, and clinical outcome.this prospective study is going to investigate whether 68ga-dotatate pet/ct may be superior to 18f-fdg pet/ct for diagnosis, risk stratification, and prognostic evaluation of net.

Eligibility criteria:
inclusion criteria: * suspected or confirmed untreated net patients previously performed 18f-fdg pet/ct signed written consent. exclusion criteria: * pregnancy breastfeeding known allergy against tate any medical condition that in the opinion of the investigator, may significantly interfere with study compliance.
pmmhri-pitavastatin registry

Conditions: Hypercholesterolemia

Summary: the pmmhri-pitavastatin registry is a non-interventional, single-center registry conducted at the polish mother's memorial hospital research institute (pmmhri). established in january 2024, the registry enrolls all patients from the department of cardiology and adult congenital heart diseases, the department of endocrinology, as well as outpatient cardiology and endocrinology clinics who are prescribed pitavastatin.

the pmmhri-pitavastatin registry is a non-interventional, single-center registry conducted at the polish mother's memorial hospital research institute (pmmhri), the second-largest supra-regional hospital in poland. the registry was initiated in january 2024 to systematically collect real-world data on patients prescribed pitavastatin, aiming to assess its effectiveness, safety, and impact on lipid and cardiovascular risk management. the registry has included all patients from the departments of cardiology and endocrinology, as well as outpatient cardiology and endocrinology clinics, who have been prescribed pitavastatin. the inclusion of a broad patient population allows for a comprehensive evaluation of treatment patterns and outcomes in routine clinical practice. patient data are extracted from electronic medical records and include: demographic parameters (age, sex, bmi, etc.) relevant comorbidities (e.g., hypertension, diabetes, chronic kidney disease) concomitant medications, including: lipid-lowering therapy status (monotherapy vs. combination therapy), anticoagulation status lifestyle factors, such as smoking status post hoc calculated cardiovascular risk scores, to stratify patients based on their predicted risk of major adverse cardiovascular events (mace) laboratory parameters, including lipid profiles, inflammatory markers, and metabolic indicators.

Eligibility criteria:
inclusion criteria: * patient takling pitavastatin based on the 2021 polish lipid guidelines exclusion criteria: -

Keywords: hypercholesterolemia pitavastatin
the effect of ioc on analgesia for elderly patients with postoperative effectiveness

Conditions: Colorectal Cancer

Summary: the morbidity of colorectal cancer and the surgery number among elderly is growing. the investigators need to provide more advanced and specific monitoring technology for these patients. index of consciousness (ioc) monitor is now widely used among endoscopy, cholecystectomy and other common clinical applications. the investigators goal is to verify whether using ioc monitor could help to improve the postoperative recovery after colorectal surgery.

participants will be randomly assigned, in a 1:1 ratio, to receive ioc monitoring or bis monitoring during the operation as the criteria for adjustment of analgesics use. the randomization sequence will be computer-generated, and randomization will be performed in blocks and will be stratified according to participating center. the number of dialysis and patient's recovery after the transplantation will be recorded. the participation of each patient is scheduled till they discharge from hospital.

Eligibility criteria:
inclusion criteria: * patients aged over 60 years old that underwent colorectal surgery in the first affiliated hospital of xi'an jiaotong university. exclusion criteria: * having severe comorbidity history,for example,severe cardiac dysfunction * having central nervous system disease, severe endocrine, and history of mental disorders * alcoholic and long-term use of sedatives and opioids history * drug allergy history.

Keywords: ioc monitor elderly postoperative effectiveness
cognitive skills training using computer for patients with severe mental illness

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: the study is designed to evaluate the effectiveness of computerized cognitive skills training for improving memory and problem-solving skills in inpatients with schizophrenia.

subjects are stable inpatients and outpatients with schizophrenia or schizoaffective disorder who are receiving atipsychotic medication at manhattan psychiatric center. patients receive baseline assessments (mccb-matrics; personal and social performance scale, fedt/feit and panss) and then are assigned to cognitive remediation (crt) using the cogpack program, patients are then randomly assigned to a social cognition program (mind reader interactive guide to emotions) for a period of 12 weeks. following 12 weeks of treatment in either crt + mind reader or crt alone, assessments are repeated by raters. cognitive remediation (crt): crt (cogpack, marker and olbrich, 1998) consists of computerized practice tests for seven cognitive domains. there are 64 programs for testing and training, each with several variants for the domains of visuomotor skills, comprehension, reaction, vigilance, memory, language, and intellectual skills. exercises in cogpack can be edited and expanded. patients attend 2 (45-minutes each) groups and 1 discussion group. social cognition training: mind reader (baron-cohen et al, 2004) is an interactive computerized program of emotions and mental states. it is based on a taxonomic system of 412 emotions and mental states, grouped into 24 emotion groups, and six developmental levels (from age 4 to adulthood). the emotions and mental states are organized systematically, according to the emotion groups and developmental levels. patients assigned to mind reader attend 1 group per week. both the crt and mind reader are administered in small groups of six to eight patients each.

Eligibility criteria:
inclusion criteria: 1. age 18 and above; 2. in- and out-patients; 3. dsm-iv diagnosis of schizophrenia (all subtypes) or schizoaffective disorder with illness duration \>5 years; 4. auditory and visual acuity adequate to complete cognitive tests; 5. stable dose of oral atypical antipsychotic for at least 4 weeks; 6. total panss score \> 60; 7. good physical health determined by physical examination from medical chart review; 8. capacity and willingness to give written informed consent. 9. mmse \> 24 exclusion criteria: 1. inability to read or speak english; 2. documented disease of the central nervous system; 3. history of intellectual impairment pre-dating onset of symptoms of psychosis (e.g. mental retardation); 4. clinically significant or unstable cardiovascular, renal, hepatic, gastrointestinal, pulmonary or hematological conditions; 5. hiv +; 6. patients diagnosed with substance dependence; 7. currently participating in another experimental study.
efficacy study of vaginal mesh for anterior prolapse

Conditions: Vaginal Prolapse; Uterine Prolapse; Cystocele; Pelvic Organ Prolapse

Summary: the primary aim of this double-blind, randomized clinical trial (rct) is to test the hypothesis that the addition of a standardized technique of interpositional synthetic polypropylene mesh placement improves the one-year outcome of vaginal reconstructive surgery for anterior prolapse compared to traditional vaginal reconstructive surgery without mesh.

multiple vaginal, abdominal and laparoscopic procedures have been described for surgical correction of pelvic support problems. however, conventional pelvic reconstructive surgeries have been associated with a 20-30% prolapse recurrence rate. the anterior vaginal wall is the site most often recognized as the area of vaginal prolapse recurrence. minimally invasive surgical procedures using mesh have rapidly developed in the field of pelvic floor reconstruction in an attempt to improve surgical cure rates. unfortunately, safety and efficacy data have lagged behind the technical advancements. this trial will randomize women with advanced anterior wall prolapse to two treatment arms: vaginal reconstructive surgery with mesh and vaginal reconstructive surgery without mesh. the primary outcome is cure of anterior wall prolapse at one year. secondary outcomes are cure of apical and posterior wall prolapse, quality-of-life measures and complication rates. patients will be approached for recruitment only after they have made the decision to undergo vaginal surgery for anterior prolapse. the patient and examiner will be blinded to the surgical treatment assignment. interim measurement of primary and secondary outcomes will be conducted three months post-operatively. additional follow-up will be conducted at one-year intervals subsequent to the expected one-year endpoint.

Eligibility criteria:
inclusion criteria: 1. women age \> 21 2. diagnosed with stage ii-iv vaginal prolapse who desire reconstructive surgery 3. available for 12 months of follow-up 4. able to complete study questionnaires and assessments. 5. available for 12 months follow-up exclusion criteria: 1. uterus in place. 2. no anterior vaginal prolapse. 3. medical contraindications, e.g. current urinary tract, vaginal or pelvic infection, history of pelvic irradiation, history of lower urinary tract malignancy, chronic steroid use or a compromised immune system. 4. current intermittent self catheterization. 5. pregnancy or desire for future fertility. 6. presence of an adnexal or ovarian mass. 7. shortened vagina. 8. other laparoscopic or abdominal/pelvic surgery in the past 3 months.\* 9. known neurologic or medical condition affecting bladder function, e.g. multiple sclerosis, spinal cord injury. 10. need for surgery requiring an abdominal incision. 11. \<12 months post-partum. (enrollment can be deferred until time requirement has been met).

Keywords: prolapse uterus mesh bladder
e-alcohol therapy - an evaluation of alcohol therapy delivered via video conference

Conditions: Problematic Alcohol Use

Summary: the study evaluates whether the introduction of e-alcohol therapy (alcohol therapy delivered via video conference) can break with some of the barriers related to alcohol treatment and thereby appeal to people with a problematic alcohol use (alcohol use disorder test score ≥ 8). the study aims to evaluate the effect of e-alcohol therapy on initiation, treatment compliance and alcohol intake as compared to treatment as usual .

background: only a small proportion of those who have a problematic alcohol use receive treatment and compliance is low among the few that undergo treatment. if treatment more easily can be combined with everyday life and break with some of the barriers related to stigma by having a broader appeal, more people with a problematic alcohol use may seek and complete treatment. alcohol therapy conducted via video conference may be an attractive treatment option and effective in reducing alcohol intake among people with a problematic alcohol use who do not seek traditional treatment. objective: the aim of this trial is to evaluate whether people with a problematic alcohol use (alcohol use disorder test score ≥ 8), who enroll in alcohol therapy delivered via video conference to a greater extent initiate as well as comply with treatment and reduce their alcohol intake compared to people allocated to standard alcohol treatment. design: randomized controlled trial participants: 375 danish citizens above 18 years with a problematic alcohol use (alcohol use disorder test (audit) score \>8). intervention: participants are randomized to one of two groups: 1. conversational therapy via video conference where participants are contacted by an alcohol therapist for the purpose of initiating a course of treatment where participants are not required to show up at a clinic. 2. treatment as usual where participants receive contact information on their local alcohol treatment facility for the purpose of contacting the facility to initiate a face-to-face course of treatment at the clinic. the allocation of participants to the intervention will be 1:1 to the intervention and the control group. methods: data will be collected by questionnaire at baseline, 3 months and 12 months post randomization. analyses will be intention to treat. subgroup analysis will be conducted in relation to personal and demographic characteristics. process evaluation will be performed using a combination of questionnaires and qualitative interviews with participants, therapists and management at the clinics.

Eligibility criteria:
inclusion criteria: - problematic alcohol consumption (alcohol use disorder test score ≥ 8) exclusion criteria: * not legally able and willing to provide informed consent * no provision of a functional e-mail address * no provision of municipality of residence and phone number * no access to a personal computer equipped with functional camera, audio equipment, and internet access.

Keywords: e-alcohol therapy online alcohol treatment internet-based alcohol treatment alcohol intervention video therapy proactivity
nociception level-guided remifentanil dosing in children during general anesthesia

Conditions: Surgical Procedure, Unspecified

Summary: the investigators aim to investigate whether administration of a short-acting opioid (remifentanil) guided by a pain monitor (nociceptive level monitor) during anesthesia, can reduce pain in children after surgery. the investigators hypothesize that pain monitor-guided administration of remifentanil can reduce pain postoperatively compared with standard care.

nol-guided analgesia has not previously been assessed in children, and it is unknown whether this additional monitoring has any clinical benefits in a pediatric population. in the present study the investigators aim to investigate whether administration of perioperative remifentanil guided by the ce-certified pain monitoring device monitor-pmd200™, also called nol-monitor, can reduce pain (primary endpoint), opioid consumption and agitation in children aged 3-16 years undergoing surgery with intravenous anesthesia. the investigators hypothesize that nol-guided perioperative remifentanil administration can reduce postoperative pain compared with standard clinical care (remifentanil dosing based on hemodynamic variables). all patients will receive standard analgesia and antiemetic administered perioperatively: * iv paracetamol 15 mg/kg * iv ibuprofen 10 mg/kg, unless contraindicated * iv morphine 25-100 μg/kg according to the extent of surgery and the departments' standard, administered 30 minutes before end of surgery (will not be included in the total perioperative or postoperative opioid consumption) * in case of minor surgery, 1-2 μg/kg fentanyl, according to the department's standard, may be administered instead of morphine at the discretion of the anesthetist (will not be included in the total perioperative or postoperative opioid consumption) * regional anesthesia may be provided at the discretion of the anesthetist * iv ondansetron 100 μg/kg

Eligibility criteria:
inclusion criteria: * american society of anesthesiology (asa) class of 1-3 * scheduled surgery requiring intraoperative opioid administration * planned maintenance anesthesia with propofol and remifentanil * the trial subject's custody holders' must be able to understand the trial protocol, risks, and benefits, and provide signed informed consent exclusion criteria: * inability of the trial subject's custody holder to read or write danish * children who cannot cooperate to the study assessments based on the investigators' evaluation. this may be children with mental disorders, visual disturbances, hearing or speech impairment etc. interfering with assessments. * arrythmias, either known arrythmias preoperatively or arrythmias detected within the first minutes perioperatively (in which case the patient will be excluded post- randomization). * allergy to the medicines used in the study * daily intake of opioids (morphine, oxycodone, ketobemidone, methadone, fentanyl) during the last 4 weeks * weight \< 10 kg

Keywords: pediatric pain
study of the long term efficacy of recombinant hepatitis b vaccine in nile delta of egypt

Conditions: Hepatitis B Vaccines

Summary: more than two billion individuals have serological evidence of hepatitis b virus (hbv) infection worldwide. of these, 240 million are chronic carriers and approximately 786,000 hepatitis b related deaths occur annually. currently available hepatitis b vaccines are extremely safe and have an efficacy of \>90 percent against all hbv serotypes and genotypes. thus, hbv infection can potentially be eradicated through global vaccination. a positive immune response to the vaccine is defined as the development of hepatitis b surface antibody (anti-hbs) at a titer of \>10 miu/ml. although anti-hbs titers decrease with time, the duration of protection is long. protection has been estimated to persist for up to 22 years after the primary vaccination schedule. protection from clinical disease, despite declining or even undetectable anti-hbs levels, is probably due to the priming of memory cells, which are capable of eliciting an anamnestic response when challenged. this is supported by the rapid increases in anti-hbs titers in previously vaccinated individuals who administered booster injections.

a significant proportion of the vaccinated population loses both the protective levels of anti-hbs and an anamnestic response. recommendations for booster vaccination have been proposed in a european consensus statement. countries like the netherlands, germany, spain, france and belgium recommend a booster dose depending on the post-vaccination anti-hbs titer. in the uk, a single booster dose is recommended five years after primary vaccination. in egypt, the routine infant immunization for hepatitis b virus started in 1992, and was given at 2nd, 4th and 6th months of age. in the present study the investigators will investigate the long term efficacy of hepatitis b vaccination in young adults 20 to 22 years after the primary vaccination in nile delta of egypt.

Eligibility criteria:
inclusion criteria: * age 20-22 years * administration of hbv vaccine during routine infant immunization (2nd, 4th, 6th months after birth) exclusion criteria: * overt co-morbid condition * treatment with immune-modulatory or immune-suppressive drugs
tranexamic acid versus placebo for blood to reduce perioperative bleeding post-liver resection

Conditions: Cancer; Tumour; Surgery

Summary: tranexamic acid (txa) is an antifibrinolytic agent that has been shown to reduce blood loss and blood transfusion requirements in the following patient populations: multisystem trauma, liver transplantation, cardiac surgery and spine surgery. patients undergoing major liver resection are at risk of severe perioperative blood loss and may also benefit from perioperative txa administration. this open label, non-randomized study to evaluate the pharmacokinetic and pharmacodynamic properties of two well studied dosing regimens of txa will provide guidance in determining the optimal txa dosing regimen for patients undergoing major liver resection. compelling evidence of the effectiveness of txa comes from the large multicentred, multi-national crash-2 trial where txa was administered as a 1 g bolus + 1 g infusion over 8 hours. in liver transplant surgery, the following dose regimen has been shown to have great effect:10 mg/kg/h from the start of surgery until 2 hours after reperfusion of the liver transplant. although txa is not currently approved for use in patients undergoing major liver resection, health canada has allowed the use of tranexamic acid for use in this research study.


Eligibility criteria:
inclusion criteria * patient undergoing anticipated open or laparoscopic major liver resection (\> 2 hepatic segments), as assessed by the operating surgeon * age ≥ 18 years. exclusion criteria * previously enrolled in this study * platelet count less than 100,000/mm3 * severe anemia (hemoglobin levels less than 90 g/l) * documented arterial or venous thrombosis at screening or in past three months * anticoagulants (other than lmwh or heparin in prophylactic doses to prevent deep vein thrombosis), direct thrombin inhibitors or thrombolytic therapy administered or completed within last week * hepatectomy associated with planned vascular or biliary reconstruction * known disseminated intravascular coagulation * severe renal insufficiency (crcl\<30) * history of seizure disorder * pregnant or lactating * hypersensitivity to tranexamic acid or any of the ingredients * unable to receive blood products (i.e. difficulty with cross matching, refuses blood transfusion, or a past history of unexplained severe transfusion reaction) * receipt of chemotherapy within 4 weeks of scheduled operation * patients undergoing resection for living donor liver transplant.

Keywords: blood transfusion blood loss postoperative complications outcome